A single center, open-label, fixed sequence, two-period study to investigate the effect of memantine on pharmacokinetics, safety and tolerability of RO5313534 after single dose administration in healthy volunteers and the effect of RO5313534 on safety and tolerability of steady state memantine
Phase of Trial: Phase I
Latest Information Update: 10 Jun 2016
At a glance
- Drugs RG 3487 (Primary) ; Memantine
- Indications Alzheimer's disease
- Focus Pharmacokinetics
- Sponsors Roche
- 18 Apr 2011 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 21 Mar 2011 Planned End Date changed from 1 Dec 2010 to 1 Mar 2011.
- 15 Oct 2010 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.